Abstract:Sialic acid-binding immunoglobulin-like lectins, also known as Siglecs, have recently been designated as glyco-immune checkpoints. Through their interactions with sialylated glycan ligands overexpressed on tumor cells, inhibitory Siglecs on innate and adaptive immune cells modulate signaling cascades to restrain anti-tumor immune responses. However, the elucidation of the mechanisms underlying these processes is just beginning. We find that when human natural killer (NK) cells attack tumor cells, glycan remodeling occurs on the target cells at the immunological synapse. This remodeling occurs through both the transfer of sialylated glycans from NK cells to target tumor cells and the accumulation of de novo synthesized sialosides on the tumor cells. The functionalization of NK cells with a high-affinity ligand of Siglec-7 leads to multifaceted consequences in modulating a Siglec-7-regulated NK-activation. At high levels of ligand, an enzymatically added Siglec-7 ligand suppresses NK cytotoxicity through the recruitment of Siglec-7 to an immune synapse, whereas at low levels of ligand an enzymatically added Siglec-7 ligand triggers the release of Siglec-7 from the cell surface into the culture medium, preventing a Siglec-7-mediated inhibition of NK cytotoxicity. These results suggest that a glycan engineering of NK cells may provide a means to boost NK effector functions for related applications.With the formation of an immune synapse during an NK-based killing, a cancer cell upregulates its cell-surface sialylation level primarily via an accumulation of neosialylation, and its mediated immune inhibition can be blocked with a cis high-affinity ligand created chemoenzymatically, which resulted in a better tumor growth control.This article has not yet been cited by other publications.

Modulation of Immune Tolerance via Siglec-Sialic Acid Interactions

Siglec-mediated regulation of immune cell function in disease

Sialic Acid-Siglec Axis in Human Immune Regulation, Involvement in Autoimmunity and Cancer and Potential Therapeutic Treatments

Siglecs as Immune Cell Checkpoints in Disease

Targeting the Siglec–Sialic Acid Immune Axis in Cancer: Current and Future Approaches

Current Status on Therapeutic Molecules Targeting Siglec Receptors

Targeting Siglec–Sialylated MUC1 Immune Axis in Cancer

Advances in understanding and exploiting Siglec–glycan interactions

Functions and therapeutic targets of Siglec-mediated infections, inflammations and cancers

Suppressing Immune Responses Using Siglec Ligand-Decorated Anti-receptor Antibodies

Modulation of Siglec-7 Signaling Via In Situ-Created High-Affinity cis -Ligands

Bridging the Gap Between Tolerogenic Dendritic Cells In Vitro and In Vivo: Analysis of Siglec Genes and Pathways Associated with Immune Modulation and Evasion

Decoration of T-independent Antigen with Ligands for CD22 and Siglec-G Can Suppress Immunity and Induce B Cell Tolerance in Vivo

Siglec Receptors Modulate Dendritic Cell Activation and Antigen Presentation to T Cells in Cancer

Therapeutic potential to target sialylation and SIGLECs in neurodegenerative and psychiatric diseases

The glycoimmune checkpoint receptor Siglec-7 interacts with T-cell ligands and regulates T-cell activation

Structural insights into Siglec-15 reveal glycosylation dependency for its interaction with T cells through integrin CD11b

The intriguing roles of Siglec family members in the tumor microenvironment

Sialic acid and Siglec receptors in tumor immunity and immunotherapy

The sialic acid-Siglec immune checkpoint: an opportunity to enhance immune responses and therapy effectiveness in melanoma

Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2